These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24736396)

  • 1. PSA screening for prostate cancer.
    Wilt TJ; Dahm P
    BMJ; 2014 Apr; 348():g2559. PubMed ID: 24736396
    [No Abstract]   [Full Text] [Related]  

  • 2. A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits.
    Black A
    Evid Based Med; 2014 Oct; 19(5):186. PubMed ID: 24939923
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of recommendations against prostate cancer screening with prostate specific antigen].
    Abascal Junquera JM; Fumadó Ciutat L; Francés Comalat A; Cecchini Rosell L
    Med Clin (Barc); 2016 Oct; 147(8):361-365. PubMed ID: 27085747
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
    Welch HG; Albertsen PC
    N Engl J Med; 2020 Apr; 382(16):1557-1563. PubMed ID: 32294352
    [No Abstract]   [Full Text] [Related]  

  • 7. Should you skip your PSA test? The science is uncertain for now, so arm yourself with deep knowledge of the pros and cons of prostate cancer screening.
    Harv Mens Health Watch; 2012 Oct; 17(3):1, 7. PubMed ID: 23175860
    [No Abstract]   [Full Text] [Related]  

  • 8. To screen or not to screen for prostate cancer?
    Lancet; 2012 Jun; 379(9831):2024. PubMed ID: 22656872
    [No Abstract]   [Full Text] [Related]  

  • 9. Balancing the harms and benefits of early detection of prostate cancer.
    van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
    Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 11. [Systematic PSA screening has been tried in Region Skåne. Balanced information gives chance for equal treatment according to a pilot project].
    Bratt O; Lundgren R; Ahlgren G
    Lakartidningen; 2012 Sep 12-18; 109(37):1610-2. PubMed ID: 23077769
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    McKenzie PR; Delahunt B; Kench JG; Sikaris KA
    Pathology; 2014 Jan; 46(1):91-2. PubMed ID: 24300730
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    Zardawi IM
    Pathology; 2014 Jan; 46(1):91. PubMed ID: 24300722
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA screening: the case in favor.
    Nguyen PL; Hyatt AS; Devlin PM
    Oncology (Williston Park); 2013 Oct; 27(10):980, 982. PubMed ID: 24367854
    [No Abstract]   [Full Text] [Related]  

  • 17. PSA screening for colorectal cancer patients: proceeding with caution.
    Olsen JR; Michalski JM
    Oncology (Williston Park); 2013 Oct; 27(10):1041-2. PubMed ID: 24367866
    [No Abstract]   [Full Text] [Related]  

  • 18. PSA screening: Back to the future.
    Klein E
    Cleve Clin J Med; 2018 Nov; 85(11):881-883. PubMed ID: 30395520
    [No Abstract]   [Full Text] [Related]  

  • 19. An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.
    Crawford ED; Rosenberg MT; Partin AW; Cooperberg MR; Maccini M; Loeb S; Pettaway CA; Shore ND; Arangua P; Hoenemeyer J; Leveridge M; Leapman M; Pinto P; Thompson IM; Carroll P; Eastham J; Gomella L; Klein EA
    Urology; 2016 Oct; 96():116-120. PubMed ID: 27450937
    [No Abstract]   [Full Text] [Related]  

  • 20. PSA screening: good evidence shows little benefit, significant harms.
    LeFevre M; Moyer V
    Oncology (Williston Park); 2013 Oct; 27(10):981-2. PubMed ID: 24367855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.